Klaria Pharma initiates clinical program for Naloxone Alginate Film to prevent opioid overdose
Klaria Pharma Holding AB (publ) announces that tthe Naloxone Alginate Film has entered into clinical phase of development. GMP production of the product has been initated and the first clinical s developing Naloxone Alginate Film as a co-prescription to opiods for patients at high risk of opiod use disorder. Klaria estimates the total addressable market for co-prescription of naloxone is worth 1.9 billion USD in the United States alone.“After having secured a financing round of 27 MSEK, we are now expanding Klaria’s operations and launching the clinical program for Naloxone Alginate Film